Intrinsic value of FibroGen - FGEN

Previous Close

$40.36

  Intrinsic Value

$2.66

stock screener

  Rating & Target

str. sell

-93%

Previous close

$40.36

 
Intrinsic value

$2.66

 
Up/down potential

-93%

 
Rating

str. sell

We calculate the intrinsic value of FGEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 3.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  45.20
  41.18
  37.56
  34.31
  31.38
  28.74
  26.36
  24.23
  22.30
  20.57
  19.02
  17.62
  16.35
  15.22
  14.20
  13.28
  12.45
  11.70
  11.03
  10.43
  9.89
  9.40
  8.96
  8.56
  8.21
  7.89
  7.60
  7.34
  7.10
  6.89
Revenue, $m
  182
  258
  354
  476
  625
  805
  1,017
  1,264
  1,545
  1,863
  2,218
  2,608
  3,035
  3,497
  3,993
  4,524
  5,087
  5,682
  6,309
  6,967
  7,656
  8,376
  9,126
  9,907
  10,720
  11,566
  12,444
  13,358
  14,307
  15,293
Variable operating expenses, $m
  238
  335
  461
  620
  814
  1,048
  1,324
  1,645
  2,012
  2,426
  2,888
  3,396
  3,952
  4,553
  5,199
  5,890
  6,623
  7,398
  8,214
  9,071
  9,968
  10,905
  11,882
  12,899
  13,958
  15,059
  16,203
  17,392
  18,627
  19,911
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  238
  335
  461
  620
  814
  1,048
  1,324
  1,645
  2,012
  2,426
  2,888
  3,396
  3,952
  4,553
  5,199
  5,890
  6,623
  7,398
  8,214
  9,071
  9,968
  10,905
  11,882
  12,899
  13,958
  15,059
  16,203
  17,392
  18,627
  19,911
Operating income, $m
  -55
  -78
  -107
  -144
  -189
  -243
  -307
  -382
  -467
  -563
  -670
  -788
  -917
  -1,056
  -1,206
  -1,366
  -1,536
  -1,716
  -1,905
  -2,104
  -2,312
  -2,529
  -2,756
  -2,992
  -3,238
  -3,493
  -3,758
  -4,034
  -4,321
  -4,618
EBITDA, $m
  -46
  -65
  -90
  -121
  -159
  -204
  -258
  -321
  -392
  -473
  -563
  -662
  -770
  -887
  -1,013
  -1,148
  -1,291
  -1,442
  -1,601
  -1,768
  -1,943
  -2,125
  -2,316
  -2,514
  -2,720
  -2,935
  -3,158
  -3,389
  -3,630
  -3,880
Interest expense (income), $m
  0
  10
  5
  18
  35
  57
  83
  115
  152
  196
  245
  301
  364
  432
  507
  589
  676
  770
  869
  974
  1,084
  1,200
  1,321
  1,448
  1,580
  1,718
  1,861
  2,010
  2,164
  2,325
  2,492
Earnings before tax, $m
  -65
  -83
  -125
  -179
  -246
  -326
  -422
  -534
  -662
  -808
  -971
  -1,151
  -1,349
  -1,564
  -1,795
  -2,042
  -2,306
  -2,585
  -2,879
  -3,188
  -3,512
  -3,851
  -4,204
  -4,572
  -4,955
  -5,354
  -5,768
  -6,198
  -6,646
  -7,111
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -65
  -83
  -125
  -179
  -246
  -326
  -422
  -534
  -662
  -808
  -971
  -1,151
  -1,349
  -1,564
  -1,795
  -2,042
  -2,306
  -2,585
  -2,879
  -3,188
  -3,512
  -3,851
  -4,204
  -4,572
  -4,955
  -5,354
  -5,768
  -6,198
  -6,646
  -7,111

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  361
  509
  700
  941
  1,236
  1,591
  2,010
  2,497
  3,054
  3,683
  4,383
  5,155
  5,998
  6,911
  7,892
  8,940
  10,053
  11,229
  12,468
  13,769
  15,130
  16,552
  18,035
  19,580
  21,187
  22,857
  24,594
  26,398
  28,274
  30,223
Adjusted assets (=assets-cash), $m
  361
  509
  700
  941
  1,236
  1,591
  2,010
  2,497
  3,054
  3,683
  4,383
  5,155
  5,998
  6,911
  7,892
  8,940
  10,053
  11,229
  12,468
  13,769
  15,130
  16,552
  18,035
  19,580
  21,187
  22,857
  24,594
  26,398
  28,274
  30,223
Revenue / Adjusted assets
  0.504
  0.507
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
  0.506
Average production assets, $m
  183
  259
  356
  478
  628
  808
  1,021
  1,269
  1,552
  1,871
  2,227
  2,619
  3,047
  3,511
  4,009
  4,542
  5,107
  5,705
  6,334
  6,995
  7,687
  8,409
  9,162
  9,947
  10,763
  11,612
  12,494
  13,411
  14,364
  15,354
Working capital, $m
  -105
  -149
  -204
  -275
  -361
  -464
  -587
  -729
  -892
  -1,075
  -1,280
  -1,505
  -1,751
  -2,018
  -2,304
  -2,610
  -2,935
  -3,279
  -3,640
  -4,020
  -4,418
  -4,833
  -5,266
  -5,717
  -6,186
  -6,673
  -7,180
  -7,707
  -8,255
  -8,824
Total debt, $m
  52
  186
  358
  574
  840
  1,159
  1,537
  1,975
  2,476
  3,042
  3,672
  4,367
  5,126
  5,947
  6,830
  7,773
  8,775
  9,834
  10,949
  12,120
  13,345
  14,625
  15,959
  17,349
  18,795
  20,299
  21,862
  23,486
  25,174
  26,928
Total liabilities, $m
  325
  458
  630
  847
  1,112
  1,432
  1,809
  2,248
  2,749
  3,314
  3,945
  4,640
  5,398
  6,220
  7,103
  8,046
  9,048
  10,107
  11,222
  12,392
  13,617
  14,897
  16,232
  17,622
  19,068
  20,572
  22,134
  23,759
  25,446
  27,201
Total equity, $m
  36
  51
  70
  94
  124
  159
  201
  250
  305
  368
  438
  516
  600
  691
  789
  894
  1,005
  1,123
  1,247
  1,377
  1,513
  1,655
  1,804
  1,958
  2,119
  2,286
  2,459
  2,640
  2,827
  3,022
Total liabilities and equity, $m
  361
  509
  700
  941
  1,236
  1,591
  2,010
  2,498
  3,054
  3,682
  4,383
  5,156
  5,998
  6,911
  7,892
  8,940
  10,053
  11,230
  12,469
  13,769
  15,130
  16,552
  18,036
  19,580
  21,187
  22,858
  24,593
  26,399
  28,273
  30,223
Debt-to-equity ratio
  1.450
  3.650
  5.110
  6.100
  6.800
  7.290
  7.640
  7.910
  8.110
  8.260
  8.380
  8.470
  8.550
  8.610
  8.650
  8.700
  8.730
  8.760
  8.780
  8.800
  8.820
  8.840
  8.850
  8.860
  8.870
  8.880
  8.890
  8.900
  8.900
  8.910
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -65
  -83
  -125
  -179
  -246
  -326
  -422
  -534
  -662
  -808
  -971
  -1,151
  -1,349
  -1,564
  -1,795
  -2,042
  -2,306
  -2,585
  -2,879
  -3,188
  -3,512
  -3,851
  -4,204
  -4,572
  -4,955
  -5,354
  -5,768
  -6,198
  -6,646
  -7,111
Depreciation, amort., depletion, $m
  9
  12
  17
  23
  30
  39
  49
  61
  75
  90
  107
  126
  147
  169
  193
  218
  246
  274
  305
  336
  370
  404
  440
  478
  517
  558
  601
  645
  691
  738
Funds from operations, $m
  -56
  -71
  -108
  -156
  -215
  -287
  -373
  -473
  -588
  -718
  -864
  -1,025
  -1,202
  -1,395
  -1,602
  -1,824
  -2,060
  -2,310
  -2,574
  -2,852
  -3,142
  -3,446
  -3,763
  -4,094
  -4,438
  -4,795
  -5,167
  -5,554
  -5,955
  -6,372
Change in working capital, $m
  -33
  -43
  -56
  -70
  -86
  -104
  -122
  -142
  -163
  -183
  -204
  -225
  -246
  -267
  -286
  -306
  -325
  -344
  -362
  -380
  -397
  -415
  -433
  -451
  -469
  -488
  -507
  -527
  -548
  -569
Cash from operations, $m
  -23
  -27
  -52
  -86
  -129
  -184
  -250
  -331
  -425
  -535
  -659
  -800
  -956
  -1,128
  -1,316
  -1,518
  -1,735
  -1,967
  -2,213
  -2,472
  -2,745
  -3,031
  -3,330
  -3,643
  -3,969
  -4,308
  -4,660
  -5,027
  -5,408
  -5,803
Maintenance CAPEX, $m
  -6
  -9
  -12
  -17
  -23
  -30
  -39
  -49
  -61
  -75
  -90
  -107
  -126
  -147
  -169
  -193
  -218
  -246
  -274
  -305
  -336
  -370
  -404
  -440
  -478
  -517
  -558
  -601
  -645
  -691
New CAPEX, $m
  -57
  -75
  -97
  -122
  -150
  -180
  -213
  -247
  -283
  -319
  -356
  -392
  -428
  -464
  -498
  -532
  -565
  -598
  -629
  -661
  -692
  -722
  -753
  -785
  -816
  -849
  -882
  -917
  -953
  -990
Cash from investing activities, $m
  -63
  -84
  -109
  -139
  -173
  -210
  -252
  -296
  -344
  -394
  -446
  -499
  -554
  -611
  -667
  -725
  -783
  -844
  -903
  -966
  -1,028
  -1,092
  -1,157
  -1,225
  -1,294
  -1,366
  -1,440
  -1,518
  -1,598
  -1,681
Free cash flow, $m
  -86
  -111
  -162
  -225
  -302
  -394
  -502
  -627
  -769
  -928
  -1,105
  -1,299
  -1,511
  -1,738
  -1,983
  -2,243
  -2,519
  -2,810
  -3,116
  -3,437
  -3,773
  -4,123
  -4,488
  -4,868
  -5,263
  -5,674
  -6,101
  -6,544
  -7,005
  -7,484
Issuance/(repayment) of debt, $m
  -46
  134
  172
  216
  266
  320
  377
  438
  501
  566
  630
  695
  759
  822
  883
  943
  1,002
  1,059
  1,115
  1,170
  1,225
  1,280
  1,335
  1,390
  1,446
  1,504
  1,563
  1,624
  1,688
  1,754
Issuance/(repurchase) of shares, $m
  222
  98
  145
  203
  275
  362
  464
  582
  718
  871
  1,041
  1,229
  1,433
  1,655
  1,893
  2,147
  2,417
  2,702
  3,003
  3,318
  3,648
  3,993
  4,352
  4,726
  5,116
  5,521
  5,942
  6,379
  6,833
  7,306
Cash from financing (excl. dividends), $m  
  176
  232
  317
  419
  541
  682
  841
  1,020
  1,219
  1,437
  1,671
  1,924
  2,192
  2,477
  2,776
  3,090
  3,419
  3,761
  4,118
  4,488
  4,873
  5,273
  5,687
  6,116
  6,562
  7,025
  7,505
  8,003
  8,521
  9,060
Total cash flow (excl. dividends), $m
  90
  120
  155
  194
  239
  287
  339
  394
  450
  508
  566
  624
  681
  738
  793
  847
  900
  951
  1,002
  1,051
  1,100
  1,150
  1,199
  1,248
  1,299
  1,351
  1,404
  1,459
  1,516
  1,576
Retained Cash Flow (-), $m
  -222
  -98
  -145
  -203
  -275
  -362
  -464
  -582
  -718
  -871
  -1,041
  -1,229
  -1,433
  -1,655
  -1,893
  -2,147
  -2,417
  -2,702
  -3,003
  -3,318
  -3,648
  -3,993
  -4,352
  -4,726
  -5,116
  -5,521
  -5,942
  -6,379
  -6,833
  -7,306
Prev. year cash balance distribution, $m
  650
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  518
  22
  10
  -9
  -37
  -75
  -125
  -189
  -268
  -363
  -475
  -604
  -752
  -917
  -1,100
  -1,300
  -1,517
  -1,751
  -2,001
  -2,267
  -2,548
  -2,843
  -3,153
  -3,478
  -3,817
  -4,170
  -4,538
  -4,920
  -5,317
  -5,730
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  497
  20
  9
  -7
  -28
  -54
  -84
  -118
  -154
  -190
  -225
  -258
  -286
  -308
  -323
  -330
  -330
  -323
  -308
  -288
  -264
  -236
  -207
  -177
  -148
  -122
  -97
  -76
  -58
  -43
Current shareholders' claim on cash, %
  50.0
  35.1
  24.3
  16.7
  11.4
  7.8
  5.4
  3.7
  2.6
  1.8
  1.2
  0.8
  0.6
  0.4
  0.3
  0.2
  0.1
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

FINANCIAL RATIOS  of  FibroGen (FGEN)

Valuation Ratios
P/E Ratio -41.4
Price to Sales 14.3
Price to Book 16.5
Price to Tangible Book
Price to Cash Flow 367
Price to Free Cash Flow 428.2
Growth Rates
Sales Growth Rate -0.6%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -50%
Cap. Spend. - 3 Yr. Gr. Rate -32.2%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 71.8%
Total Debt to Equity 71.8%
Interest Coverage 0
Management Effectiveness
Return On Assets -13.2%
Ret/ On Assets - 3 Yr. Avg. -15.5%
Return On Total Capital -22.2%
Ret/ On T. Cap. - 3 Yr. Avg. -24.1%
Return On Equity -37.1%
Return On Equity - 3 Yr. Avg. -40%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -31.1%
EBITDA Margin - 3 Yr. Avg. -38.6%
Operating Margin -29.4%
Oper. Margin - 3 Yr. Avg. -36.1%
Pre-Tax Margin -34.4%
Pre-Tax Margin - 3 Yr. Avg. -41.8%
Net Profit Margin -34.4%
Net Profit Margin - 3 Yr. Avg. -41.8%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

FGEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the FGEN stock intrinsic value calculation we used $125.668 million for the last fiscal year's total revenue generated by FibroGen. The default revenue input number comes from 0001 income statement of FibroGen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our FGEN stock valuation model: a) initial revenue growth rate of 45.2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for FGEN is calculated based on our internal credit rating of FibroGen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of FibroGen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of FGEN stock the variable cost ratio is equal to 130.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for FGEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.9% for FibroGen.

Corporate tax rate of 27% is the nominal tax rate for FibroGen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the FGEN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for FGEN are equal to 100.4%.

Life of production assets of 20.8 years is the average useful life of capital assets used in FibroGen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for FGEN is equal to -57.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $528.467 million for FibroGen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 83.522 million for FibroGen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of FibroGen at the current share price and the inputted number of shares is $3.4 billion.

RELATED COMPANIES Price Int.Val. Rating
AKBA Akebia Therape 7.92 0.54  str.sell
BMY Bristol-Myers 53.27 71.64  hold
AZN AstraZeneca AD 41.40 162.71  str.buy
PTCT PTC Therapeuti 33.26 214.00  str.buy
ABBV AbbVie 90.14 174.70  str.buy
PFE Pfizer 43.21 34.10  hold

COMPANY NEWS

▶ FibroGen: 3Q Earnings Snapshot   [05:35PM  Associated Press]
▶ Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms   [Sep-24-18 11:10AM  American City Business Journals]
▶ FibroGen: 2Q Earnings Snapshot   [06:13PM  Associated Press]
▶ FibroGen to Present at Two Upcoming Investor Conferences   [Jun-04-18 02:05PM  GlobeNewswire]
▶ FibroGen: 1Q Earnings Snapshot   [May-09-18 05:31PM  Associated Press]
▶ FibroGen reports 4Q loss   [Feb-28-18 05:04AM  Associated Press]
▶ FibroGen, Inc. to Host Earnings Call   [01:30PM  ACCESSWIRE]
▶ FibroGen Q4 Earnings Outlook   [12:53PM  Benzinga]
▶ ETFs with exposure to FibroGen, Inc. : December 27, 2017   [Dec-27-17 11:15AM  Capital Cube]
▶ ETFs with exposure to FibroGen, Inc. : December 15, 2017   [Dec-15-17 01:21PM  Capital Cube]
▶ ETFs with exposure to FibroGen, Inc. : November 20, 2017   [Nov-20-17 12:27PM  Capital Cube]
▶ ETFs with exposure to FibroGen, Inc. : November 8, 2017   [Nov-08-17 06:07PM  Capital Cube]
▶ FibroGen reports 3Q loss   [05:31PM  Associated Press]
▶ FibroGen, Inc. to Host Earnings Call   [02:10PM  ACCESSWIRE]
▶ Is It Too Late To Buy FibroGen Inc (FGEN)?   [07:29AM  Simply Wall St.]
▶ ETFs with exposure to FibroGen, Inc. : October 24, 2017   [Oct-24-17 09:38AM  Capital Cube]
▶ ETFs with exposure to FibroGen, Inc. : October 13, 2017   [Oct-13-17 10:47AM  Capital Cube]
▶ Cramer's lightning round: Let Nike walk these losses off   [Oct-10-17 07:04PM  CNBC Videos]
▶ 3 Under-the-Radar Small Cap Gems   [Oct-02-17 11:14AM  Investopedia]
▶ FibroGen Inc (FGEN): How Does It Impact Your Portfolio?   [Sep-30-17 07:17AM  Simply Wall St.]
▶ FibroGen Appoints Gerald Lema to Board of Directors   [Sep-19-17 04:35PM  GlobeNewswire]
▶ Why This Cancer Biotech Leads Pack After Hitting Record High   [Sep-13-17 04:33PM  Investor's Business Daily]
▶ Is There Now An Opportunity In FibroGen Inc (FGEN)?   [Sep-06-17 07:14PM  Simply Wall St.]
▶ Why Ralph Lauren, LendingClub, and FibroGen Jumped Today   [Aug-08-17 04:20PM  Motley Fool]
▶ Why FibroGen Inc Skyrocketed Higher Today   [02:37PM  Motley Fool]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.